Imagine a future where the key to saving thousands of lives might lie in the genes of a pig—sounds extraordinary, right? But here’s where it gets controversial—in recent groundbreaking research, scientists have successfully kept a human alive using a liver transplanted from a genetically modified pig. This isn’t just an experiment; it’s a glimpse into a potentially revolutionary approach to tackling the devastating global shortage of donor organs. The experiment lasted 171 days, providing crucial evidence that engineered pig livers can perform vital metabolic and synthetic functions within a human body. Yet, despite this remarkable progress, the journey toward long-term success is paved with complex medical and technical obstacles that still need to be overcome.
According to the World Health Organization, each year, thousands of individuals perish while waiting for donated organs—a crisis primarily driven by the stark scarcity of human tissue donors. In China alone, hundreds of thousands develop liver failure annually, but in 2022, only around 6,000 liver transplants were performed. This significant gap between organ demand and supply underscores the importance of innovative alternatives, such as xenotransplantation, the process of transplanting organs between different species.
The First-Ever Human Liver Transplant Using a Genetically Engineered Pig
The patient involved was a 71-year-old man battling hepatitis B-related cirrhosis and liver cancer. Unfortunately, he didn’t qualify for traditional treatment options like surgical removal of tumors or a human liver transplant. Instead, surgeons implanted an auxiliary liver from a specially engineered pig—a Diannan miniature pig with ten specific genetic modifications. These modifications included removing antigens that typically provoke rejection by the human immune system and adding human genes to enhance compatibility, aiming to reduce immune and blood clotting issues post-transplant.
In the initial month, the pig liver performed well, producing bile and synthesizing clotting factors—clear signs that it was functioning properly without immediate rejection. However, on day 38, complications arose. The patient developed xenotransplantation-associated thrombotic microangiopathy (xTMA), a dangerous blood vessel injury linked to immune activation. This adverse event was addressed with treatments like eculizumab, a drug that inhibits complement activation, and plasma exchange. Unfortunately, the patient later suffered recurrent gastrointestinal bleeding and passed away on day 171.
Expert Insights: What Does This Mean for the Future?
Dr. Beicheng Sun, the lead scientist behind this study, emphasized the significance of the breakthrough, stating, “This case proves that a genetically engineered pig liver can function in a human for an extended period.
